A 24-month, Multicenter, Randomized, Open Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration Controlled Certican in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral versus 1.44 Myfortic with Standard Dose Neoral

Grants and Contracts Details

StatusFinished
Effective start/end date8/25/0510/31/10

Funding

  • Novartis (domestic): $292,287.00